Is Candida glabrata susceptible to micafungin and caspofungin, and do these agents achieve adequate urine concentrations for treating urinary tract infections?

Echinocandins Are NOT Recommended for Candida Urinary Tract Infections

Micafungin and caspofungin should NOT be used as first-line therapy for Candida glabrata urinary tract infections because both agents achieve minimal urinary concentrations and are generally ineffective for treating UTIs. 1

Critical Pharmacokinetic Problem

The fundamental issue is urinary excretion. The 2016 IDSA guidelines explicitly state that "all other antifungal drugs, including the other azole agents and echinocandins, have minimal excretion of active drug into the urine and generally are ineffective in treating Candida UTI" 1. The FDA label for micafungin does not list urinary tract infections as an approved indication 2.

Candida glabrata Susceptibility

While C. glabrata is generally susceptible to both micafungin and caspofungin from a microbiological standpoint 3, this in vitro susceptibility is clinically irrelevant for UTIs because:

• The drugs don't reach adequate concentrations in urine
• Susceptibility testing doesn't predict clinical efficacy when drug delivery to the infection site is inadequate

Recommended Treatment Algorithm for C. glabrata UTI

First-Line Options:

1. Fluconazole-susceptible C. glabrata: Fluconazole 200-400 mg daily for 2 weeks 1
2. Fluconazole-resistant C. glabrata: Amphotericin B deoxycholate 0.3-0.6 mg/kg daily for 1-7 days, with or without flucytosine 25 mg/kg four times daily 1
3. Alternative for resistant strains: Flucytosine monotherapy 25 mg/kg four times daily for 2 weeks (weak recommendation) 1

When Echinocandins Might Be Considered (Exceptional Circumstances Only):

The guidelines acknowledge that echinocandins have been used "primarily because of UTI due to fluconazole-resistant organisms, and both success and failure were reported" 1. However, this should only occur when:

• Hematogenous renal infection (not ascending UTI): Tissue concentrations may be adequate even though urine levels are not 1
• All other options contraindicated: When amphotericin B toxicity is prohibitive and flucytosine is unavailable or contraindicated 4, 5, 6, 7

Evidence Nuances

Case reports show mixed results: Small case series report successful treatment of C. glabrata UTI with micafungin 8, 6, 7, 9 and caspofungin 4, 5, but these are anecdotal and contradict guideline recommendations. One series achieved mycological cure in 6/7 patients with caspofungin 5, while another reported successful micafungin treatment in complicated cases 6.

Critical caveat: These case reports involved:

• Complicated infections with renal insufficiency 4
• Fluconazole-resistant strains with no alternatives 8, 6
• Therapeutic drug monitoring to optimize dosing 8

Common Pitfalls to Avoid

1. Don't assume in vitro susceptibility equals clinical efficacy for UTIs with echinocandins
2. Don't use lipid formulations of amphotericin B for UTI—they don't achieve adequate urine concentrations 1
3. Don't forget source control: Remove or replace urinary catheters, nephrostomy tubes, or stents when feasible 1
4. Don't overlook obstruction: Eliminate any urinary tract obstruction, which is strongly recommended 1

Bottom Line

Use fluconazole for susceptible strains, amphotericin B deoxycholate ± flucytosine for resistant strains. Reserve echinocandins only for hematogenous renal candidiasis or when all standard options are contraindicated, recognizing this is off-guideline use with unpredictable outcomes.